Floatz logo

Continuous Microgestin 1/20

Migraine Disorder

Endeavor HealthUNKNOWNPhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

101 Active assets in the Migraine Disorder cohort.

Asset / SponsorPhaseRating
Atogepant
Stanford University
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
Ubrogepant
H. Lundbeck A/S
Phase 4BBB

View all 50 →

Same molecule, other indications

Continuous Microgestin 1/20 is also rated in:

interstitial cystitisDormant
BB
Indicative · Phase 4
69 / 100
View asset →
dysmenorrheaDormant
BB
Indicative · Phase 4
69 / 100
View asset →
endometriosisDormant
BB
Indicative · Phase 4
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →